Basilea Pharmaceutica AG


$36.9 CHF

$0.6 (1.65%)

Average Volume
Market Capitalization
P/E Ratio
Dividend Yield
Price Target
Year High
Year Low
Payout Ratio
Current Ratio

Industry, Sector & symbol

Stock Exchange Swiss Exchange
CEO Mr. David Veitch
Industry Biotechnology
Sector Healthcare
Current Symbol BSLN.SW
CIK None
Phone 41 61 606 11 11
Currency CHF
Employees 143
Country CH


Debt-to-Equity Ratio -4.16
Payout Ratio 0.00
Current Ratio 2.34
Quick Ratio 1.98
Cash Ratio 1.13

Sales & Book Value

Annual Sales $157.63M
Price / Sales 3.00
Cash Flow 0.32
Price / Cash Flow 118.02
Price / Book -9.72

Price Target and Rating

Average Stock Price Forecast $
High Stock Price Forecast $
Low Stock Price Forecast $
Forecast Upside/Downside %
Consensus Rating Buy
Rating Score(0-5) 4
Research Coverage 0 Analysts


EPS (Most Recent Fiscal Year) $0.86
Trailing P/E Ratio 36.03
PEG Ratio 11.84
P/E Growth 11.84
Net Income $10.45M
Net Margin 8.22%
Pretax Margin 8.19%
Return on Equity -23.45%
Return on Assets 5.50%

Financials Score

AltmanZ Score -3.80
Piotroski Score 3.00
Working Capital 118.64M
Total Assets 230.03M
Ebit -18.12M
Market Cap 437.33M
Total Liabilities 215.04M

Poll Results

About Basilea Pharmaceutica AG (SIX:BSLN.SW) Stock

Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing Derazantinib, a small molecule inhibitor, wh ... ich is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.

Frequently Asked Questions

What is the current Basilea Pharmaceutica AG (BSLN.SW) stock price?

Basilea Pharmaceutica AG(SIX:BSLN.SW) stock price is $36.9 in the last trading session. During the trading session, BSLN.SW stock reached the peak price of $54.5 while $32.0 was the lowest point it dropped to. The percentage change in BSLN.SW stock occurred in the recent session was 1.65% while the dollar amount for the price change in BSLN.SW stock was $0.6.

BSLN.SW's industry and sector of operation?

The SIX listed BSLN.SW is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of BSLN.SW?

Dr. Peer Nils Schroder | Head of Corporate Communications & Investor Relations
Mr. Damian Heller | General Counsel & Corporate Secretary
Ms. Ursula Eberhardt | Head of Global Human Resources
Mr. Mark Jones | Head of Project Management & Preclinical Development
Dr. Laurenz Kellenberger Ph.D. | Chief Scientific Officer

How many employees does BSLN.SW have?

Number of BSLN.SW employees currently stands at 143. BSLN.SW operates from Grenzacherstrasse 487, Basel, None 4058, CH.

Link for BSLN.SW official website?

Official Website of BSLN.SW is:

How do I contact BSLN.SW?

BSLN.SW could be contacted at phone #41 61 606 11 11 and can also be accessed through its website. BSLN.SW operates from Grenzacherstrasse 487, Basel, None 4058, CH.

How many shares of BSLN.SW are traded daily?

The average number of BSLN.SW shares traded daily for last 3 months was 32.28K.

What is the market cap of BSLN.SW currently?

The market value of BSLN.SW currently stands at $442.92M with its latest stock price at $36.9